Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 5Myelodysplastic Syndromes 2Myeloproliferative Disorders 1Leukemia, Myeloid 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Biphenotypic, Acute 1Blast Crisis 1

Interventions

Cyclophosphamide 8asciminib 7fludarabine phosphate 6fludarabine 5Mycophenolic Acid 5nilotinib 3Whole-Body Irradiation 3Thiotepa 3Tacrolimus 3Imatinib Mesylate 3Granulocyte Colony-Stimulating Factor 3Cyclosporine 3venetoclax 2Sirolimus 2Melphalan 2Filgrastim 2Dasatinib 2Cyclosporins 2treosulfan 1thymoglobulin 1selinexor 1ruxolitinib 1ponatinib 1plerixafor 1olverembatinib 1midostaurin 1merphos 1gilteritinib 1bosutinib 1blinatumomab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myelogenous, Chronic, BCR-ABL Positive × gilteritinib × 30 days × Clear all
NCT02115295 2026-05-20

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

M.D. Anderson Cancer Center

Phase 2 Recruiting
508 enrolled
MyeloidOther hematologic neoplasm

Blast Crisis, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡